Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 6, 2007, Pages 1235-1240

  How, Priscilla P ^a   Fischer, James H ^a   Arruda, Jose A ^a   Lau, Alan H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; LANTHANUM; LANTHANUM CARBONATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG INTERACTION; FEMALE; HUMAN; INTESTINE ABSORPTION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TIME;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CIPROFLOXACIN; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INTESTINAL ABSORPTION; LANTHANUM; MALE; MIDDLE AGED; TIME FACTORS;

EID: 38449089436     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01580407     Document Type: Article

References (28)

1. Tokras JI, Miller ER, Stein G: New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control 30: 288-295, 2002
2. Radandt JM, Marchbanks CR, Dudley MN: Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 14: 272-284, 1992
3. Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT: Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 36: 830-832, 1992
4. Sahai J, Healy DP, Stotka J, Polk RE: The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol 35: 302-304, 1993
5. Lomaestro BM, Bailie GR: Quinolone-cation interactions: A review. DICP 25: 1249-1258, 1991
6. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM: Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 42: 1253-1259, 2003
7. Chiang SS, Chen JB, Yang WC: Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 63: 461-470, 2005
8. Finn WF, Joy MS, Hladik G, Lanthanum Study Group: Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 62: 193-201, 2004
9. Joy MS, Finn WF, LAM-302 Study Group: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42: 96-107, 2003
10. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 85: S73-S78, 2003
11. 1999 Metropolitan height and weight tables for men and women, Metropolitan Life Insurance Company, 1999. Available at: http:// www.bcbst.com/mpmanual/HW.htm. Accessed March 2006
12. Granneman GR, Varga LL: High-performance liquid chromatographic procedures for the determination of temafloxacin in biological matrices. J Chromatogr 568: 197-206, 1991
13. Center for Drug Evaluation and Research, US Department of Health and Human Services, Food and Drug Administration: Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, Rockville, MD, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003
14. Davis RL, Koup JR, Williams-Warren J, Weber A, Smith AL: Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother 28: 74-77, 1985
15. Fiddler G, Webster I: Lanthanum carbonate is well tolerated when administered with warfarin and has no effect on its pharmacokinetics [Abstract]. Presented at the National Kidney Foundation Clinical Meeting; April 2 through 6, 2003; Dallas, TX
16. Fiddler G, Taubel J: Lanthanum carbonate has no effect on the pharmacokinetics of digoxin and can be administered safely in combination [Abstract]. Presented at the National Kidney Foundation Clinical Meeting; April 2 through 6, 2003; Dallas, TX
17. Fiddler G, Taubel J: Lanthanum carbonate has a good safety profile following concomitant administration with metoprolol and has no clinically significant effect on its pharmacokinetics [Abstract]. Presented at the National Kidney Foundation Clinical Meeting; April 2 through 6, 2003; Dallas, TX
18. Fiddler G, Taubel J: Lanthanum carbonate (Fosrenol) does not affect the pharmacokinetics of digoxin or warfarin. Paper presented at the Ninth Asian Pacific Congress of Nephrology; February 16 through 20, 2003; Pattaya, Thailand
19. Product information: Fosrenol® (Lanthanum carbonate), Wayne, PA, Shire US Inc., 2005
20. Appelbaum PC, Hunter PA: The fluoroquinolone antibacterials: Past, present and future perspectives. Int J Antimocrob Agents 16: 5-15, 2000
21. Brittain DC, Scully BE, McElrath MJ, Steinman R, Labthavikul P, Neu HC: The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. J Clin Pharmacol 25: 82-88, 1985
22. Hoffken G, Lode H, Prinzing C, Borner K, Koeppe P: Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 27: 375-379, 1985
23. Gonzalez MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, Painter B: Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26: 741-744, 1984
24. Wingender W, Graefe KH, Gau W, Forster D, Beermann D, Schacht P: Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol 3: 355-359, 1984
25. Lomaestro BM, Bailie GR: Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 35: 1004-1007, 1991
26. Lomaestro BM, Bailie GR: Effect of multiple staggered dose of calcium on the bioavailability of ciprofloxacin. Ann Pharmacother 27: 1325-1328, 1993
27. Product information: Cipro® (ciprofloxacin hydrochloride), West Haven, CT, Bayer Pharmaceuticals Corp., 2005
28. Product information: Renagel® (sevelamer hydrochloride), Cambridge, MA, Genzyme Corp., 2004